|Year : 2009 | Volume
| Issue : 2 | Page : 214-216
Vandana Mehta, Vani Vasanth, C Balachandran
Department of Skin and STD, Kasturba Medical College, Manipal, Karnataka, India
Department of Skin and STD, Kasturba Medical College, Manipal-576 104, Karnataka
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Mehta V, Vasanth V, Balachandran C. Pap smear. Indian J Dermatol Venereol Leprol 2009;75:214-6
| Introduction|| |
Cervical cancer is predominantly sexually transmitted and the association between certain oncogenic (high risk) strains of human papillomavirus (HPV) and cervical cancer is well documented.  It has been shown worldwide that screening for precursors of cervical cancer by means of Papanicoloau (Pap) smears substantially reduces the incidence of invasive cancer.
| Definition|| |
A Pap smear More Details, also known as Papanicoloau smear, is a microscopic examination of cells scraped from the cervix and is used to detect cancerous or pre-cancerous conditions of the cervix or other medical conditions. It was named after Dr. George N. Papanicoloau, who first described it in 1928 and since its introduction, the Pap smear has helped reduce cervical cancer incidence and mortality rates by 75%. The Pap smear is a screening tool that looks for changes in the transformation zone of the cervix, which most often are caused by HPV.
| Method of Sample Collection|| |
The cervix is composed of columnar epithelium, which lines the endocervical canal, and squamous epithelium, which covers the exocervix. The point at which they meet is called the squamocolumnar junction. Metaplasia advances from the original squamocolumnar junction inwards toward the external os and over the columnar villi, which establishes an area called the transformation zone. It is this area that the sample is taken from for the Pap smear. Screening with conventional Pap testing should occur every year. If liquid-based cytology (LBC) is being used, screening can be extended to every 2 years. Screening should begin at the age of 21 or within 3 years of the onset of sexual activity and it can stop at the age of 70 years if there has been no abnormal Pap test result in the past 10 years. 
A Pap test should be performed during the second half of the menstrual cycle (Day 14). Sample collection usually begins with appropriate instruction to the patient. Patients must abstain from sexual intercourse and avoid using any vaginal medication or contraceptives 48 h before sample collection. The patient is placed in lithotomy position and the cervix is visualized by means of a speculum. The smaller end of the Ayre's spatula is introduced through the external os and the squamocolumnar junction is scraped by rotating the spatula to 360°. The scraping is then evenly spread onto a glass slide, which is immediately fixed using 95% ethyl alcohol and ether to avoid air drying artifacts. 
| What is an Adequate Smear?|| |
An adequate smear is the one with the following features:
- Adequate numbers of squamous epithelial cells present.
- Evidence that the transformation zone was sampled (i.e. the presence of endocervical cells on the smear).
- Spread in a relatively even monolayer.
- Epithelial cells not obscured by blood, inflammatory cells, or foreign material such as lubricant or talc.
- Appropriately preserved.
| Interpretation of a Normal PAP Smear|| |
The following three types of cells are seen in a normal Pap smear:
In addition, endometrial cells, histiocytes, blood cells and bacteria may also be seen. The presence of atypical cells indicates an abnormal Pap smear, which could be a result of either inflammation caused by an infection or cervical atypia [Figure 1].
- Cells from the basal layer, which are small, rounded and basophilic with large nuclei, 
- Cells from the intermediate layer, which are basophilic with vesicular nuclei  and
- Cells from the superficial layer, which are acidophilic with pyknotic nuclei. 
| PAP Smear Reporting|| |
The Pap smear reporting classification has evolved and been refined over time. The current reporting system is the Bethesda system, which was introduced in 1988  and later updated again in 1999 [Table 1]. 
Patients with abnormal Pap smear who do not have a gross cervical lesion are usually evaluated by colposcopy- and colposcopy-directed biopsy. Colposcopy can detect low- and high-grade dysplasia but does not detect microinvasive disease. Colposcopy is the study of cervical morphology using stereoscopic binocular magnification provided by the colposcope. This instrument provides a 3-dimensional image of the examined tissue surfaces and its use is now routinely recommended for the evaluation of abnormal Pap smears. In screening programs aimed at detecting and eliminating cervical cancer and pre-cancer, colposcopy plays an important adjunctive role with cytology and histology. If no abnormalities are found or if the entire squamocolumnar junction cannot be visualized, a cervical cone biopsy or HPV DNA test is performed.
| Limitations of PAP Smear|| |
- Inadequate samples constitute about 8% of the specimens received.
- False-negative results as high as 20-30% have been reported, which occurred due to clumping of cells when the cells are not uniformly spread on the glass slide.
- Sometimes, other contents of the cervical specimen such as blood, bacteria and yeasts contaminate the sample and prevent the detection of abnormal cells.
- If exposed to air for too long before being fixed on the slide, cervical cells can become distorted.
- Human error is probably the primary threat to accurate interpretation. An average Pap smear slide contains 50,000-300,000 cells that must be examined and if the sample contains only a few abnormal cells within a crowded background of healthy cells, the abnormal cells may be missed.
| Newer Techniques|| |
A conventional Pap smear has a sensitivity ranging from 47 to 62% and a specificity of 60-90%. In order to minimize the number of false-negative results, LBC is now the preferred method of sample collection where a cervical brush is used to collect the specimen, which provides almost twice as many epithelial cells. The samples are collected directly in a preservative solution and slides are prepared meticulously avoiding any uneven manual smearing and thus reducing human error while interpretation. LBC has got a higher sensitivity and specificity than Pap smear as the cellular structure is better preserved because the cells are fixed immediately.  Another way to improvise the Pap smear diagnosis is by using stains to detect the HPV antigens. 
| Conclusion|| |
All sexually active women must have a Pap smear examination annually to detect cervical cancer. If the smear is abnormal, it is repeated at 3-6 monthly intervals. Three abnormal results in a row is a definite indicator for further evaluation.
| References|| |
|1.||Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al . Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9. [PUBMED] [FULLTEXT]|
|2.||Sitas F, Carrara H, Terblanche M, Madhoo J. Screening for cancer of the cervix. S Afr Med J 1997;87:620-2. [PUBMED] |
|3.||Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al . American Cancer Society guidelines for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342-62. [PUBMED] [FULLTEXT]|
|4.||Suresh B. Cervical smear collection procedures. In: Gynaecological cytology cervix. 1st ed. New Delhi: Interprint; 1996. p. 141-52. |
|5.||Howkins, Bourne. Gynaecological diagnosis. In: Padubidri VG, Shirish ND, editors. Shaw's textbook of gynaecology, 13th ed. Noida: Elsevier; 2004. p. 68-81. |
|6.||Solomon D. The 1988 Bethesda system for reporting cervical/vaginal cytologic. JAMA 1989;262:931-4. |
|7.||Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al . The 2001 Bethesda System: Terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9. |
|8.||Mahboobeh S, Diane S, Philip EC. Cervical cancer prevention: Cervical screening. Obstet Gyneacol Clin 2007;34:739-60. |
|9.||Eileen MB. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003;16:1-17. |